JG
BBIO icon

Jefferies Group’s BridgeBio Pharma BBIO Stock Holding History

Jefferies Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-223,100
Closed -$3.72M – 1541
2021
Q4 		$3.72M Buy
223,100
+173,100
+346% +$7.32M 0.02% 576
2021
Q3 		$2.34M Buy
+50,000
New +$2.68M 0.02% 710

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jefferies Group's BBIO Position: Q1 2022 in Review

Jefferies Group sold out of BridgeBio Pharma (BBIO) in Q1 2022, closing a stake of 232,019 shares — an estimated $3.87M sold.

Jefferies Group first reported a position in BBIO in Q3 2019 and held it in 5 quarters. The position peaked at $13.4M in Q2 2021. 178 funds tracked by Wall St. Rank hold BBIO as of Q1 2022.

  • Jefferies Group reported no remaining BridgeBio Pharma position as of Q1 2022 after selling out during the quarter.
  • Jefferies Group sold 232,019 BridgeBio Pharma shares in Q1 2022, an estimated $3.87M.
  • Jefferies Group first reported a position in BridgeBio Pharma in Q3 2019 and held it in 5 quarters.
  • Jefferies Group's BridgeBio Pharma position peaked at $13.4M in Q2 2021.
  • 178 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2022.

Based on Jefferies Group's 13F filing for Q1 2022, filed 16 May 2022.